Eidd 2801 Clinical Trial
Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19. Data from this study supported submission of a phase 2/3 clinical trial protocol to the US Food and Drug Administration (FDA) within 8 weeks of initial protocol submission, with FDA comments permitting phase 2 study initiation within two additional weeks. Our results show that therapeutic and prophylactic administration of EIDD-2801an oral broad-spectrum antiviral agent that is currently in phase II/III clinical trialsmarkedly inhibited...
Are there any ongoing clinical trials for EIDD-2801? Yes, Phase 3 trials for influenza and RSV are underway, with results expected in 2024, expanding its therapeutic applications beyond COVID-19. Title: A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers (EIDD-2801-1001-UK) When the pandemic began, the team quickly turned its attention to developing EIDD-2801 as a treatment for COVID-19.
DRIVE licensed EIDD-2801, now known as molnupiravir, to Ridgeback Biotherapeutics in 2020, which conducted the first human clinical trials and then partnered with Merck. Designed as a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of EIDD-2801 on SARS-CoV-2 Virus Shedding in Newly Hospitalized Adults with polymerase chain reaction (PCR)-Confirmed COVID-19. Exploratory Virologic Objective To evaluate the efficacy of EIDD-2801 to clear SARS-CoV-2 RNA and infectious virus.
In this study, we established fundamental EIDD-2801 efficacy paradigms against pandemic and seasonal influenza A virus (IAV) strains in ferrets that can be used to inform exposure targets and treatment regimens. A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2 Viral RNA Detection in Persons with COVID-19
